Human carboxylesterase 1 (hCE1) is a serine esterase involved in both drug metabolism and activation, as well as other biological processes. hCE1 catalyses the hydrolysis of heroin and cocaine, and the transesterification of cocaine in the presence of ethanol to the toxic metabolite cocaethylene. We have determined the crystal structures of hCE1 in complex with either the cocaine analogue homatropine or the heroin analogue naloxone. These are the first structures of a human carboxylesterase, and they provide details about narcotic metabolism in humans. hCE1's active site contains rigid and flexible pockets, explaining the enzyme's ability to act both specifically and promiscuously. hCE1 has also been reported to contain cholesteryl ester hydrolase, fatty acyl-CoA hydrolase and acyl-CoA:cholesterol acyltransferase activities, and thus appears to be involved in cholesterol metabolism. Since the enzyme may be useful as a treatment for cocaine overdose, and may afford protection against chemical weapons like Sarin, Soman and VX gas, hCE1 could serve as both a drug and a drug target. Selective hCE1 inhibitors targeted to several sites on the enzyme may also pave the way for novel clinical tools to manage cholesterol homoeostasis in humans.
Introduction
Human carboxylesterase 1 (hCE1) is a broad-spectrum serine hydrolase involved in drug and xenobiotic metabolism, as well as several additional biological processes. hCE1 is primarily expressed in the liver, with lesser amounts in the intestine, kidney, lung, testes, heart, monocytes and macrophages [1, 2] . The enzyme shares 47% sequence identity with human intestinal carboxylesterase (also called human carboxylesterase 2; hCE2), which exhibits a distinct expression profile and a preferred set of substrates [3] . hCE1's catalytic triad, composed of Ser-221, Glu-353 and His-467, employs a two-step hydrolysis mechanism. In the first step, a covalent acyl-enzyme intermediate is formed with the catalytic serine residue, and the alcohol product is released. In the second step, a water molecule attacks the acyl-enzyme linkage, releasing the acyl product [1] . Compounds other than water can attack the acyl-enzyme intermediate, leading to transesterification rather than hydrolysis.
The primary biological role of hCE1 appears to be xenobiotic metabolism. The enzyme is able to cleave ester, amide and thioester linkages in a wide variety of chemically distinct compounds [1] . Several clinical drugs are metabolized by hCE1, including cocaine, heroin, meperidine, demerol Key words: cholesterol metabolism, cocaine, heroin, human carboxylesterase 1 inhibitor, X-ray crystallography.
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and lidocaine [4] [5] [6] , and the enzyme processes pro-drugs like lovastatin to their active forms in vivo [7] . hCE1 cleaves the methyl ester linkage on R-cocaine to generate benzoylecgonine, the primary urinary metabolite of cocaine detected in humans ( Figure 1a ). hCE1 is also the only enzyme known to generate the toxic cocaine metabolite cocaethylene, formed when cocaine and alcohol are abused together [8] . hCE1 efficiently cleaves the 3-acetyl linkage, and, to a lesser extent, the 6-acetyl linkage on heroin to generate 6-monoacetylmorphine and morphine respectively [9] . Single-site mutations in the active site of hCE1 also convert the enzyme into an efficient organophosphate hydrolase capable of detoxifying potent nerve agents. The United States military is developing variant forms of hCE1 into a prophylactic treatment for personnel at risk of exposure to chemical weapons such as Sarin, Tabun and VX gas [10] .
The second biological role of hCE1 appears to be the processing of cholesterol and fatty acids in the liver and peripheral tissues (Figure 1b) . Although there are many enzymes involved in cholesterol metabolism and trafficking, hCE1 has been shown to be the bile-salt-independent cholesteryl ester hydrolase (CEH) found in monocytes, macrophages and hepatocytes [11] , and to also have fatty acyl-CoA hydrolase activity [12] . In addition, hCE1 has been reported to act as an acyl-CoA:cholesterol acyl-transferase (ACAT), capable of transferring a fatty acid from an acylCoA to cholesterol [13] . Thus hCE1 appears to be able to catalyse both the creation and the elimination of cholesteryl esters using transesterification and hydrolysis reactions respectively. Overexpression of hCE1 in vitro induces the efflux of cholesterol from the cell [14] . These ester transferase and hydrolase activities are crucial to the transportation of cholesterol substrates within, and among, cells and tissues [11, 15] . hCE1 and its homologues in other mammals are also essential for testosterone synthesis [16] , retinol metabolism [15] and the creation of fatty acid ethyl esters (FAEEs), the toxic metabolites associated with chronic alcohol abuse [12] .
The third biological role of hCE1 is the trafficking and retention of proteins in the endoplasmic reticulum (ER), where hCE1 is modified by N-linked glycosylation sites. While in the ER, hCE1 has been shown to bind directly to the C-reactive protein (CRP) and to hold this small protein before its release into the plasma [17] . CRP is secreted in response to tissue injury, and is the most sensitive marker identified to date for the development of atherosclerosis [18] . Reduction of hCE1's affinity for CRP is accountable for the release of CRP during acute injury, at levels up to 1000-fold higher than normal [19] . In addition, hCE1 (also called egasyn) binds to the phase II drug metabolism β-glucuronidase enzymes in the ER. The β-glucuronidase enzymes generate glucuronic acid conjugates of xenobiotic and endobiotic compounds, and mark them for elimination by efflux pumps [20] . It appears that organophosphate compounds are capable of inducing the release of β-glucuronidase from the ER by disrupting the β-glucuronidase-hCE1 complex [21] .
We recently reported the crystal structure of a rabbit carboxylesterase (rCE), the first structure of a mammalian carboxylesterase [22] . rCE shares 81% sequence identity with hCE1 [23] . We found that the monomeric rCE enzyme is an α/β-hydrolase related in structure to the acetylcholinesterases (AcChEs), but with a large and conformable active site. rCE is the most efficient enzyme identified to date in the conversion of the anticancer drug CPT-11 into its active metabolite, SN-38, a member of the camptothecin family of topoisomerase I poisons. A leaving group of CPT-11 activation, 4-piperidino-piperidine, binds in our structure not at the active site of rCE, but at a surface site separated from the active one by a thin wall of amino acid side chains. We termed this the 'side door' and proposed that it may shuttle small substrates or products into or out of the catalytic site of the enzyme [22] . The side door is related in function to the 'back door' in the AcChEs, which was proposed to facilitate the release of small products from the enzyme's active site. The side door in rCE is structurally distinct from the back door in AcChE, however, and is located in a discrete region of the active site. The side door in mammalian CEs may play an important role in the varied catalytic actions of these enzymes, as discussed below.
Heroin and cocaine metabolism by hCE1
We have determined the crystal structure of hCE1 in complex with the cocaine analogue homatropine to 2.8 Å resolution (1 Å = 0.1 nm), and with the heroin analogue naloxone to 2.9 Å resolution (Figure 2 ) [24] . These are the first structures of a human carboxylesterase or a human enzyme bound to analogues of cocaine or heroin, and they provide explicit details about narcotic metabolism in humans. hCE1 shares Figure 2 Surface representation of the hCE1 trimer, viewed from above, relative to the active-site cavities of the enzyme The substrate-binding gorge, the 'side door' and the 'Z site' are indicated in each monomer with white, red and blue arrows respectively. a 1.0 Å root-mean-square deviation over 455 equivalent Cα positions with rCE, but exhibits several distinct structural features. hCE1's oligomerization state is in equilibrium between a trimer with C3 symmetry and a stacked hexamer with 32-point group symmetry. The active sites of the enzyme are buried in the hexamer, although the side door regions are freely exposed and face out into solvent, whether the enzyme is a trimer or a hexamer. Whereas two 17-amino-acid loops proposed to cover the active site in rCE were disordered and not observed in that structure, these loops are well ordered in the hCE1 structures and close over the catalytic gorge of the enzyme. The binding of ligands to a surface Z-site on hCE1 shifts the trimer-hexamer equilibrium to trimer. Thus this surface position likely functions as an allosteric binding site, as has been proposed for a related mammalian carboxylesterase [25] .
The active site of hCE1 contains a small, rigid pocket and a large, flexible region [24] . The small ester linkages of cocaine and heroin pack into the small, rigid pocket, whereas the large, flexible pocket accommodates the structurally distinct tropine and morphine rings of cocaine and heroin respectively. These structural results, elucidated from the crystal structures of hCE1 with the cocaine analogue homatropine and the heroin analogue naloxone, explain how hCE1 is able to act both promiscuously and specifically in narcotic metabolism. The enzyme specifically aligns only the methyl ester linkage of cocaine into the small, rigid pocket. The benzoyl ester linkage or the inactive S-stereoisomer of cocaine would clash sterically with the enzyme, and would not align productively for catalysis. In the structure of hCE1 with naloxone, however, the heroin analogue binds in one orientation in seven of the twelve monomers in the asymmetric unit, and in a second orientation in the remaining five. In the first orientation, the site of the 3-acetyl linkage on heroin is aligned for hydrolysis, whereas in the second orientation, the 6-acetyl linkage is aligned. This explains hCE1's ability to act on both the 3-and 6-positions on heroin. The large, flexible pocket of hCE1's active site is lined with non-polar residues and allows the structurally distinct tropine ring of homatropine, and the morphine ring of naloxone, to dock in approximately the same place. Thus hCE1 uses a combination of a small, rigid pocket and a large, flexible pocket to achieve both specificity and non-specificity in drug metabolism [24] .
hCE1 and drug discovery hCE1 may be useful as both a drug and a drug target. hCE1 converts cocaine into benzoylecgonine, the primary urinary metabolite of this narcotic [8, 9] . The enzyme's ability to form a stable hexamer is likely to enhance its ability to circulate stably in human serum [24] . Thus hCE1 may be an effective new treatment for cocaine overdose. hCE1 has several advantages over the bacterial cocaine esterase [26] and catalytic antibodies [27] that were proposed previously for this purpose. In particular, hCE1 possesses an efficient catalytic activity, and is unlikely to elicit a potent immune response. The United States military is also developing hCE1 as a prophylactic for the potential exposure to chemical weapons [10] . Single-point mutations in the active-site region of hCE1 converts the enzyme into an efficient organophosphate hydrolase capable of detoxifying Sarin, Soman, Tabun and VX gas. Both civilian and military personnel at risk of exposure to such compounds could be injected with purified forms of hCE1, which is likely to afford protection for periods of days to weeks. In addition, hCE1 may be useful in the detoxification of equipment and buildings after exposure to organophosphate toxins.
As described above, hCE1 appears to play an important role in cholesterol trafficking and metabolism. Although the details of hCE1's contribution to the creation and elimination of cholesteryl esters in particular tissues are not known, it is clear that hCE1 joins a small number of enzymes capable of contributing to these processes. The combined action of hCE1 in both hydrolysing cholesteryl esters and in transesterifying cholesterol to create cholesteryl esters raises a significant structural and mechanistic question. A similar question arises when one considers hCE1's ability to transesterify cocaine with ethanol to create cocaethylene, a long-lived toxic metabolite detected when cocaine and alcohol are abused together [8] . When the active site of hCE1 is occupied by either naloxone or homatropine in our crystal structures, there is little room for compounds larger than water to enter the active site via the top of the catalytic gorge. We have proposed that for hCE1 to be able to transesterify cocaine to cocaethylene, ethanol must gain access to the acylenzyme intermediate by passing through the side door of the enzyme [24] .
A similar mechanism may exist when hCE1 acts as a CEH, a fatty acyl CoA hydrolase, an ACAT and in FAEE synthesis. The 16-18 carbon fatty acyl tail of the cholesteryl ester, for example, may extend out from the active site of the enzyme through the side door, allowing the ester linkage of the substrate to align for catalysis. Indeed, it has been shown that a single-point mutation in a rat homologue of hCE1 converts this enzyme from a poor into an efficient CEH [28] . Based on amino acid sequence alignment, this point mutation impacts one of the four residues that creates the side door in hCE1. Thus both the active site and the side door of hCE1 may serve as targets for drug discovery and design to regulate hCE1's action in cholesterol trafficking and metabolism. Indeed, we have recently identified acridinebased compounds that selectively inhibit hCE1, but not other hCEs (hiCE, hCE2), and appear to act at the active site of the enzyme [29] . These compounds may pave the way towards unravelling the biological roles of hCE1 in cholesterol and xenobiotic metabolism in human tissues, and provide novel avenues for drug discovery and development.
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